We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
For the quarter ended March 2024, Royalty Pharma (RPRX - Free Report) reported revenue of $717 million, down 36.6% over the same period last year. EPS came in at $0.98, compared to $1.60 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Royalty Receipts- Growth Products- Cystic fibrosis franchise: $218.45 million compared to the $205.62 million average estimate based on two analysts. The reported number represents a change of +0.9% year over year.
Revenue- Royalty Receipts- Growth Products- Tysabri: $69.05 million compared to the $69.15 million average estimate based on two analysts. The reported number represents a change of -19.6% year over year.
Revenue- Royalty Receipts- Growth Products- Imbruvica: $50.06 million compared to the $49.72 million average estimate based on two analysts. The reported number represents a change of -27.5% year over year.
Revenue- Royalty Receipts- Growth Products- Xtandi: $41.01 million versus $39.52 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.3% change.
Revenue- Royalty Receipts- Growth Products- Promacta: $42.55 million versus the two-analyst average estimate of $41.38 million. The reported number represents a year-over-year change of -14.2%.
Revenue- Royalty Receipts- Growth Products- Trelegy: $70.59 million versus $67.73 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +46.2% change.
Revenue- Royalty Receipts- Growth Products- Nurtec ODT: $6.26 million compared to the $6.43 million average estimate based on two analysts. The reported number represents a change of +18.9% year over year.
Revenue- Royalty Receipts- Growth Products- Cabometyx/Cometriq: $17.83 million versus $18.27 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change.
Revenue- Royalty Receipts- Growth Products- Evrysdi: $44.95 million versus $35.51 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +156.4% change.
Revenue- Royalty Receipts- Growth Products- Trodelvy: $10.27 million compared to the $10.30 million average estimate based on two analysts. The reported number represents a change of +29.8% year over year.
Revenue- Royalty Receipts- Growth Products- Tremfya: $36.17 million versus the two-analyst average estimate of $38.47 million. The reported number represents a year-over-year change of +14.5%.
Shares of Royalty Pharma have returned -5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended March 2024, Royalty Pharma (RPRX - Free Report) reported revenue of $717 million, down 36.6% over the same period last year. EPS came in at $0.98, compared to $1.60 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Royalty Receipts- Growth Products- Cystic fibrosis franchise: $218.45 million compared to the $205.62 million average estimate based on two analysts. The reported number represents a change of +0.9% year over year.
- Revenue- Royalty Receipts- Growth Products- Tysabri: $69.05 million compared to the $69.15 million average estimate based on two analysts. The reported number represents a change of -19.6% year over year.
- Revenue- Royalty Receipts- Growth Products- Imbruvica: $50.06 million compared to the $49.72 million average estimate based on two analysts. The reported number represents a change of -27.5% year over year.
- Revenue- Royalty Receipts- Growth Products- Xtandi: $41.01 million versus $39.52 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.3% change.
- Revenue- Royalty Receipts- Growth Products- Promacta: $42.55 million versus the two-analyst average estimate of $41.38 million. The reported number represents a year-over-year change of -14.2%.
- Revenue- Royalty Receipts- Growth Products- Trelegy: $70.59 million versus $67.73 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +46.2% change.
- Revenue- Royalty Receipts- Growth Products- Nurtec ODT: $6.26 million compared to the $6.43 million average estimate based on two analysts. The reported number represents a change of +18.9% year over year.
- Revenue- Royalty Receipts- Growth Products- Cabometyx/Cometriq: $17.83 million versus $18.27 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change.
- Revenue- Royalty Receipts- Growth Products- Evrysdi: $44.95 million versus $35.51 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +156.4% change.
- Revenue- Royalty Receipts- Growth Products- Trodelvy: $10.27 million compared to the $10.30 million average estimate based on two analysts. The reported number represents a change of +29.8% year over year.
- Revenue- Royalty Receipts- Growth Products- Tremfya: $36.17 million versus the two-analyst average estimate of $38.47 million. The reported number represents a year-over-year change of +14.5%.
View all Key Company Metrics for Royalty Pharma here>>>Shares of Royalty Pharma have returned -5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.